Roupen Odabashian, Hematology/Oncology Fellow at the Karmanos Cancer Institute, shared Boris Pasche‘s, President and CEO of Karmanos Cancer Institute, post on LinkedIn, adding:
“I had a great conversation with Dr. Boris Pasche, CEO of Karmanos Cancer Institute, and Dr. Anthony Shields on an exciting new way of treating cancer.
We explored the story, science, and potential impact of TheraBionic technology, and discussed how new ideas like this may shape the future of cancer care. It is always inspiring to learn from leaders who are pushing innovation forward in oncology.
Very grateful to Dr. Pasche and Dr. Shields for their time, insight, and generosity.”
Quoting Boris Pasche‘s post:
“I am grateful to Dr. Roupen Odabashian, Host of OncoDaily Podcast, for interviewing Dr. Anthony Shields and me to produce a comprehensive review of the TheraBionic technology.
This discussion covers various aspects, including:
- The discovery of tumor-specific frequencies
- The design of a novel medical device
- Clinical trial results
- The discovery of the mechanism of action
- Regulatory approval
- Ongoing clinical studies
The TheraBionic P1 device is available for all patients with hepatocellular carcinoma who have undergone two lines of therapy. Once a physician’s prescription is received, the device is shipped directly to the patient, allowing for immediate treatment initiation.
For more information, here is the link to the physician order form
The TheraBionic P1 device is also available in Switzerland as of 2026 where it has been prescribed to several patients at the Clinique de Genolier”
Other articles featuring Roupen Odabashian and Boris Pasche on OncoDaily.